Akebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 Million
Globe Newswire•16/11/2026•08:00 ET
0
Key Highlights
- ➤Akebia (AKBA) secured an initial $60 million term-loan tranche, fully funded at closing
- ➤Akebia used proceeds to fully repay its $55 million BlackRock loan facility
- ➤Symbiotic Capital may provide up to an additional $80 million at its discretion
- ➤Loan carries 60-month maturity, interest-only period, and rate of WSJ Prime plus 4.5% or 11.5%
- ➤Akebia reaffirmed cash runway guidance of at least two years
Expert Statements
Erik Ostrowski, Chief Financial and Chief Business Officer of Akebia Therapeutics
“We are very pleased to announce this financing which enhances our operational flexibility and gives us the potential to access additional non-dilutive capital to advance our strategic initiatives. Today we also reaffirm our cash runway guidance of at least two years”
Chris York, Senior Managing Director at Symbiotic Capital
“Akebia has a portfolio of revenue-generating products and a pipeline focused on kidney disease, led by a management team with deep experience in the space”
Chris York, Senior Managing Director at Symbiotic Capital
“We are pleased to provide this financing and look forward to supporting Akebia as it executes on its business strategy.”
Initial $60 million tranche fully funded, proceeds of which were used to fully repay $55 million BlackRock loan facility
Incremental tranche of up to $80 million in term loan financing available at Symbiotic Capital’s discretion
Get started
Create a free account to read the full story.
